Title

Hammerhead Ribozymes For Target Validation

Keywords

Antisense oligonucleotide; Antisense RNA; Hammerhead ribozyme; Target validation

Abstract

Expensive failures in the pharmaceutical industry might be avoided by target validation at an early stage. Often, the full consequences of inhibiting a chosen drug target do not emerge until late in the development process. One option is to use hammerhead ribozymes as highly specific ribonucleases targeted exclusively at the mRNA encoding the target protein. The first part of this review is concerned with the mechanism and design of hammerhead ribozymes. This includes the chemistry of their action, specificity of cleavage and ability to discriminate between different mRNAs and selection of suitable cleavage sites. In considering their use for target validation, hammerhead ribozymes are divided into two categories. Endogenous ribozymes are transcribed inside the cell where they act whilst exogenous are introduced into the cell from outside. Exogenous ribozymes are synthesised chemically and must be protected against cellular nucleases. Information is provided on transfection methods and vectors that have been used with endogenous ribozymes as well as synthesis and chemical modification of exogenous ribozymes. Of proteins inhibited in cells or whole organisms, those in animal experiments are emphasised. Comparisons are made with other approaches, especially the use of antisense oligonucleotides or RNA.

Publication Date

5-18-2002

Publication Title

Expert Opinion on Therapeutic Targets

Volume

6

Issue

2

Number of Pages

235-247

Document Type

Review

Personal Identifier

scopus

DOI Link

https://doi.org/10.1517/14728222.6.2.235

Socpus ID

0036244202 (Scopus)

Source API URL

https://api.elsevier.com/content/abstract/scopus_id/0036244202

This document is currently not available here.

Share

COinS